Alzheimer Disease and Dementia

Latest News

Reviews Assess Tools to Identify, Diagnose, Treat Alzheimer Dementia

Limited tools are available for identifying, diagnosing, and treating cognitive dysfunction from Alzheimer disease.

Benzodiazepines, Z-Drugs Not Associated With Subsequent Dementia Risk

By

Emily Pond

Use of benzodiazepines, Z-drugs, or other anxiolytics was not associated with incident dementia in either the cohort or nested case-control design.

Risk for Cognitive Decline Reduced With Adherence to aMED Diet

Closer adherence to the alternative Mediterranean diet is associated with a reduced risk for cognitive decline, but not with slower decline in cognitive function.

P-tau181 Biomarker Predicts Risk of Alzheimer Dementia

By

Brandon May

Plasma phosphorylated tau181 (P-tau181) may aid in the diagnosis of Alzheimer disease (AD), a study in Natural Medicine suggests.

Sleep-Disordered Breathing Tied to Brain Changes

Sleep-disordered breathing is associated with changes in the brain, including amyloid deposition in brain regions typically involved in Alzheimer disease.

PCPs Feel Unprepared in Providing Dementia Care

Primary care physicians believe they are on the front lines of dementia care, but many feel unprepared.

Brain Amyloid Deposition and Intracranial Atherosclerotic Disease in Adults

By

Amit Akirov, MD

There is no evidence for an association between cerebral β-amyloid deposition, a marker of Alzheimer disease, and intracranial atherosclerotic plaque or stenosis.

Higher Flavonol Intake May Protect Against Alzheimer Disease

By

Amit Akirov, MD

Higher flavonol intake through food sources, mostly fruits and vegetables, may protect against the development of Alzheimer disease.

Investigational Therapies Miss Primary End Point in Alzheimer Disease Trial

By

Steve Duffy

Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.

Belsomra Labeling Updated to Include Data on Insomnia in Alzheimer Disease

By

Brian Park, PharmD

The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.